API & IP Brief: FDA CGT Approvals Review, Sodium Thiosulfate Patent Ruling & Biopharma Updates

API & IP Intelligence Brief: FDA Competitive Generic Therapy (CGT) Review & Purity Patent Rulings

Target Keywords: Competitive Generic Therapy, CGT exclusivity, FDA ANDA approvals, Zydus Lifesciences, Amneal lanreotide, Hope Medical v Accord, sodium thiosulfate patent, API purity specifications, Paragraph IV litigation, Teva R&D Day.

Six-Month FDA Competitive Generic Therapy (CGT) Review (Apr – Oct 2026)

Between April 28 and October 19, 2026, the FDA approved 45 Abbreviated New Drug Applications (ANDAs) holding Competitive Generic Therapy (CGT) designations, up from 41 in the prior six-month period. However, only 12 approvals (27%) qualified for 180-day CGT market exclusivity, continuing a downward eligibility trend from 71% in 2019 to 26% so far in 2026.

Under Section 506H of the FD&C Act, CGT incentivises entry into off-patent or sole-source drugs facing inadequate generic competition. To unlock 180-day exclusivity, the first approved applicant must have had no unexpired Orange Book patents or exclusivities at filing and must launch within 75 days of approval.

Key CGT Execution & Market Trends

  • Indian Filers Lead Approvals: Indian pharmaceutical companies secured 27 of the 45 total approvals (60%) and 7 of the 12 exclusivity-eligible products. Zydus led with 8 approvals and 3 eligible products, including the Climara Pro transdermal patch, ascorbic acid injection, and indocyanine green (already launched under exclusivity).

  • High-Barrier Dosage Forms Dominate: Complex, non-oral solid products accounted for 32 of the 45 approvals (71%) and 10 of the 12 exclusivity-eligible candidates. Sterile injectables, transdermal patches, oral solutions, and inhalers carry manufacturing hurdles that naturally restrict competition.

  • Commercial Speed Determines Exclusivity: Of the 12 eligible products, five triggered exclusivity through timely launch, led by Amneal’s high-value generic lanreotide (Somatuline Depot) prefilled syringe. Conversely, three applicants (Beloteca’s iloprost, Macleods’ rifapentine, and Umedica’s zolpidem) forfeited exclusivity by missing the 75-day launch deadline, underscoring the need to have Drug Master Files (DMFs) and launch inventory ready prior to GDUFA dates.

Intellectual Property: Delaware Court Upholds "Ultrapure" API Patents (Hope Medical v. Accord)

On October 13, 2026, the US District Court for the District of Delaware ruled entirely in favour of Hope Medical Enterprises against Accord Healthcare (a subsidiary of Intas Pharmaceuticals) regarding Sodium Thiosulfate Injection (250 mg/mL).

The litigation centred on three patents (US 11,753,301; US 8,496,973; and US 9,345,724) claiming pharmaceutical-grade sodium thiosulfate defined by strict purity specifications that simultaneously cap 22 trace impurities, including mercury (≤0.05 ppm), aluminium (≤2 ppm), and non-purgeable organic carbon (≤10 ppm).

  • Anhydrous Design-Around Fails: Accord used anhydrous sodium thiosulfate API to avoid older claims reciting the pentahydrate form. The court found infringement anyway, noting that solution concentrations are calculated on a pentahydrate basis, and upheld Hope’s continuation patent (‘301), which covers any hydrate form.

  • Purity Specifications Are Patentable: The court rejected obviousness and prosecution laches defences, holding that purifying an inorganic salt to simultaneously satisfy stringent FDA-requested limits was unpredictable rather than routine optimisation. For API manufacturers, this confirms that stringent quality thresholds and pending patent continuations can block generic entry even on century-old molecules.

Biopharma Pipeline & Regulatory Highlights

  • Teva Targets $6–7 Billion in Innovative Revenue: At its R&D Day, Teva outlined its growth trajectory under its "Pivot to Growth" strategy, having more than doubled innovative medicine revenues since 2023.

  • NeOnc Granted FDA Type B Meeting: Clinical-stage biopharma NeOnc Technologies secured a January 2027 FDA End-of-Phase meeting to discuss an accelerated approval pathway and Phase 3 confirmatory trial design for intranasal NEO100 in recurrent IDH-mutant grade 4 astrocytoma.

#PharmaIP #CompetitiveGenericTherapy #CGT #FDAApprovals #GenericDrugs #ANDA #180DayExclusivity #Zydus #Amneal #Lanreotide #SodiumThiosulfate #HopeMedical #Accord #ActivePharmaceuticalIngredients #APIPurity #ParagraphIV #Teva #NeOnc #PharmaRegulatory #DrugDevelopment
----------XX------------XX-------------XX-----------XX-------------

Contents

Competitive Generic Therapy (CGT): Six-Month Review of FDA Approvals (Apr – Oct 2026)

General information

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100

Intellectual Property

Hope Medical v. Accord (Intas): Delaware court upholds "ultrapure" sodium thiosulfate API patents against ANDA filer

Competitive Generic Therapy (CGT): Six-Month Review of FDA Approvals (Apr – Oct 2026)


Between 28 April and 19 October 2026, the FDA approved 45 generic applications (ANDAs) carrying a Competitive Generic Therapy (CGT) designation, but only 12 (27%) were eligible for the 180-day CGT exclusivity. Five of those 12 applicants launched in time and triggered their exclusivity; three forfeited it by not marketing within 75 days of approval; and four were still inside, or had only just passed, their 75-day launch window when FDA last updated its list on 22 October 2026.

Indian companies won 27 of the 45 approvals (60%) and 7 of the 12 exclusivity-eligible ones. Zydus was the most active applicant, with 8 approvals and 3 eligible products, while Amneal secured the most valuable exclusivity of the period on generic lanreotide (Somatuline Depot).

What is CGT?
CGT was created by the FDA Reauthorisation Act of 2017 (FDARA) and sits in section 506H of the FD&C Act. A generic applicant can ask FDA to designate its product as a CGT when the reference drug has "inadequate generic competition", meaning no more than one approved product (the reference drug or a generic) is listed in the active section of the Orange Book. The request is filed with, or before, the original ANDA; FDA aims to decide within 60 days, and the designation stays in place even if competition increases before approval.

The first approved applicant for a CGT can earn 180 days of CGT exclusivity under section 505(j)(5)(B)(v), provided no unexpired Orange Book patents or exclusivities were listed when the ANDA was submitted. The exclusivity starts on first commercial marketing, not on approval, and blocks FDA from approving any later ANDA for the same drug. It is forfeited if the applicant does not market the product within 75 days of approval.

How CGT helps generic filers
  • Faster, more interactive review: designated applicants can request development meetings, and FDA uses mid-review-cycle teleconferences and cross-disciplinary review teams, although designation does not guarantee a shorter GDUFA goal date.
  • 180 days of protection from later generics: for a niche product with one or no generic competitors, this window often earns most of the product's lifetime profit.
  • A route where Paragraph IV does not apply: CGT exclusivity rewards entry into off-patent, sole-source or shortage-prone products that offer no patent-challenge exclusivity.
  • The clock starts at launch, not approval, so the applicant controls when the 180 days begin, but the 75-day forfeiture rule stops it from "parking" the exclusivity.
CGT approvals in the last six months

FDA approved 45 CGT-designated ANDAs in the six months to 19 October 2026, up from 41 in the previous six months, or about seven a month (June was the peak, with 13). The share eligible for exclusivity keeps falling: it was 71% of approvals in 2019 (17 of 24), 32% in 2025 (31 of 97) and 26% so far in 2026 (19 of 72).

CGT approvals eligible for 180-day exclusivity, 28 Apr – 19 Oct 2026

12 approvals, newest first. Exclusivity end dates are estimated as 180 days from the first marketing date reported by FDA; the Orange Book CGT code is the authoritative date.


Status of CGT exclusivity

Five of the 12 eligible applicants have triggered exclusivity; three of the eight decided cases ended in forfeiture.

By dosage form

32 of the 45 approvals (71%) and 10 of the 12 eligible products are not conventional tablets or capsules.

Analysis

CGT is working as a steady channel for niche generics, but the 180-day reward now goes to a minority of filers, and only to those ready to launch quickly.
  1. Exclusivity is the exception, not the rule. Only 12 of 45 approvals were eligible. Most designated products had another applicant approved first, or patents or exclusivities listed when the ANDA was filed. More filers now chase the same niches: pitolisant (Lupin, Novitium), prucalopride (Alembic, Micro Labs) and calcium gluconate (Cipla, Caplin) each drew two CGT approvals from different applicants in this window.
  2. The 75-day rule bites. Three of the eight decided cases forfeited (iloprost, rifapentine, zolpidem 7.5 mg), compared with two of eleven in the previous six months. Two of the winners launched late in the window (DMSO on day 66, propranolol on day 70). API supply, commercial batches and distribution must be ready before approval, not after.
  3. Value sits in hard-to-make dosage forms. Sterile injectables, peptide depots, transdermal patches, oral liquids and inhalation products account for 10 of the 12 eligible approvals. Their manufacturing barriers keep competitor numbers low, which is exactly the situation CGT rewards.
  4. Indian companies dominate the list. They hold 27 of 45 approvals and 7 of 12 eligible products. Zydus leads with 8 approvals and three eligible products (Climara Pro, ascorbic acid, indocyanine green), and indocyanine green is already under exclusivity. Lupin (3), Dr. Reddy's (2), Sun (2), Cipla, Alembic, Micro Labs, Macleods, Natco, Concord, Caplin, Rubicon, Orbicular, Umedica, Encube and Aurobindo (Aurolife) also feature.
  5. Amneal holds the most valuable exclusivity of the period. Its lanreotide prefilled syringe is an ANDA generic of Somatuline Depot, marketed on 21 September 2026, with exclusivity running to about March 2027. CGT exclusivity blocks only later ANDAs; Cipla's lanreotide, approved through a 505(b)(2) NDA, is a separate product, and its US supply has been paused since late 2025 because of FDA inspection issues at its partner's plant.
  6. This analysis uses the FDA's Competitive Generic Therapy Approvals list, as updated on 22 October 2026 (approvals to 19 October 2026). As far as possible, duplicate entries were counted only once.
  7. Applicants were grouped as Indian by parent company (for example, Zydus Lifesciences Global FZE with Zydus, Aurolife with Aurobindo).
  8. Four exclusivity determinations were still open; their status may have changed after FDA's last update.
Some takeaway messages
  1. For generic filers and API makers, CGT rewards the first applicant that is both approved and on the market within 75 days. A filed DMF, secured API supply and launch stock before the GDUFA date are as important as the designation itself.
  2. The number of CGT-eligible approvals that are launched is a useful measure of a generic company's execution in niche products; in this period, Zydus and Amneal stand out.

General information

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma model
Source here

NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma. The meeting is scheduled for early January 2027.

Source here


Intellectual Property 


Hope Medical v. Accord (Intas): Delaware court upholds "ultrapure" sodium thiosulfate API patents against ANDA filer

Court: US District Court for the District of Delaware 
Decision Date: 13 October 2026 (bench trial 8–10 October 2024)
OB Listed patents


Patents in Suit: US 11,753,301; US 8,496,973; US 9,345,724, all titled "Sodium Thiosulfate-Containing Pharmaceutical Compositions" (priority 7 July 2010)
Patent Proprietor: Hope Medical Enterprises, Inc. (Hope Pharmaceuticals)
Defendant: Accord Healthcare, Inc., a wholly owned subsidiary of Intas Pharmaceuticals Ltd., which agreed to be bound by the judgment
Product: Sodium Thiosulfate Injection 250 mg/mL (NDA 203923), used with sodium nitrite for acute cyanide poisoning; Accord ANDA 217214 (12.5 g/50 mL), API made under DMF 36782

Procedural Background
Accord filed its ANDA with Paragraph IV certifications on about 29 April 2022 and sent notice letters on 13 June 2022 (973, 724 and 912 patents) and 13 October 2023 (301 patent). Hope sued on 26 July 2022 and added the 301 patent in September 2023; the 912 and 686 patents were later dropped. The case was tried to the bench in October 2024, and the court found for Hope on every issue on 13 October 2026.

The Subject Matter in Dispute
The claims are, in effect, an API specification written as a patent claim. Claim 5 of the 301 patent covers a composition made from pharmaceutical-grade sodium thiosulfate that simultaneously meets about 22 limits, including no more than 10 ppm non-purgeable organic carbon, 0.05 ppm mercury, 2 ppm aluminium, 200 ppm chloride, 0.1% sulfite, 0.5% sulfate, 3 ppm arsenic and 0.02 EU/mg endotoxin, an assay of 98–102% (anhydrous basis, by ion chromatography), microbial limits, and ICH Q3C limits for residual solvents.
The older 973 and 724 claims recite "sodium thiosulfate pentahydrate" with 32–37% water. Accord used anhydrous API (0.6–0.9% water) to avoid them. Hope then filed the 301 patent in February 2023, its eleventh continuation, to cover pharmaceutical-grade sodium thiosulfate in any hydrate form.

Ruling of the Court
  1. Infringement: the 301 patent was held infringed as a matter of law; Accord's only argument, that its ranges merely overlap the claimed ranges, is foreclosed by Sunovion v. Teva (Fed. Cir. 2013). On the 973/724 claims, the court held that a skilled person measures sodium thiosulfate in solution on a pentahydrate basis, as Accord's own label, assay validation and FDA-requested specifications did. Making the solution from anhydrous API did not avoid infringement.
  2. Obviousness rejected: Accord relied on a 1917 synthesis patent (Hutchins) plus general knowledge. A confidential 2008 FDA letter asking Hope to meet 18 additional "aspirational" specifications supplied a motivation, but not a reasonable expectation of success: purifying an inorganic salt to all limits at once was unpredictable, not routine optimisation. Long-felt need, the failure of others (unapproved products withdrawn in 2010–11) and Hope's priority review supported non-obviousness.
  3. Written description upheld: "no greater than" means from the limit of detection up to the stated value, and Example 1 (for example 0.58 ppm aluminium) showed possession. Ranges that include values that are hard to achieve are not invalid on that basis alone.
  4. No prosecution laches: filing the 301 patent about 14 years after the first application, and months after Accord's notice letter, was not unreasonable for a company with no more than two employees, and Accord showed no prejudice. Drafting claims to capture a competitor's product is legitimate (PIN/NIP v. Platte).
For API manufacturers and ANDA filers, the case carries four lessons. First, purity-specification claims can block generics even for a century-old molecule, because a generic must meet the same quality standard the innovator agreed with FDA. Second, switching to a different hydrate or salt of the API may not avoid claims to a solution, which courts may read on a calculated basis. Third, pending continuations should be part of any freedom-to-operate review, since they can be used to capture design-arounds disclosed in Paragraph IV notices. Fourth, meeting FDA-requested specifications can itself be patentable when achieving them is not routine. Accord may appeal to the Federal Circuit.

Decision here



 

Popular posts from this blog

Recent ANDA approvals by USFDA and Case BioNTech vs Withers & Rogers LLP

06 April 2026 Pharmaceutical IP & FDA Update: New 505(b)(2) Approvals and UPC Patent Rulings

Pharma IP Alert: Recent P-IV Filings for Spinraza & Austedo XR + Delhi HC’s ₹152 Cr Damages Precedent